BUY
₹2,215
₹2,340
₹2,550
15.12%
ICICI Securities' November 17, 2026 company update on Laurus Labs maintains a BUY rating. The view is supported by the growing contribution and improved sustainability of the CDMO business, sustained capacity investment and sharply stronger operating profitability.
Laurus Labs operates across generic APIs, generic finished dosage formulations, custom synthesis or CDMO, and biotechnology. It has 15 manufacturing units, including seven FDA-approved sites, 92 DMFs and approximately 9,000 KL of reactor capability.
Laurus Labs reported a strong Q2FY27, with revenue increasing 33.4 per cent YoY and 8.9 per cent QoQ to Rs 2,206 crore. ICICI Securities attributed the improvement to a favourable product mix and operating leverage.
| Metric | Q2FY27 | YoY Change | QoQ Change |
|---|---|---|---|
| Revenue | Rs 2,206 crore | 33.4% increase | 8.9% increase |
| CDMO revenue | Rs 875 crore | Approximately 86% increase | — |
| Generic formulations revenue | Rs 677 crore | 31% increase | — |
| Generic API revenue | Rs 625 crore | 1% increase | — |
| Laurus Bio revenue | Rs 29 crore | Approximately 38% decline | — |
| EBITDA | Rs 750 crore | 86.1% increase | 17.6% increase |
| EBITDA margin | 34% | 962 bps expansion | 251 bps expansion |
| Gross margin | 63% | 314 bps expansion | — |
| PAT | Rs 437 crore | — | — |
Management said CDMO growth was driven by late-stage programme execution and commercial API supplies across human and animal health. The CDMO quarterly run rate has increased from Rs 220 crore to Rs 250 crore, then to Rs 450 crore, Rs 500 crore and now approximately Rs 800 crore over two years.
A commercial-scale peptide block with more than 16,000 litres of SPPS reactor capacity has been commissioned. Peptide validation batches are expected over the next 12 to 18 months, while commercial revenue is likely from around 2029.
Management has reiterated a Rs 3,000 crore capex programme for FY27 and FY28, with significant investment in API and CDMO capacity. It expects annual capex of around Rs 1,500 crore beyond FY28, subject to opportunities.
Of more than Rs 5,180 crore of capex incurred during FY22 to FY27, about 84 per cent was directed to API and CDMO. Laurus Labs targets CDMO at about 50 per cent of revenue by FY30.
Laurus Pharma Zone, a 530-acre Andhra Pradesh site with potential investment of Rs 5,630 crore across three phases over eight years, could support the next growth-capex cycle. Management also reiterated guidance for gross margin above 60 per cent and EBITDA margin above 30 per cent.
ICICI Securities estimates revenue of Rs 8,779 crore in FY27E, Rs 10,077 crore in FY28E and Rs 11,607 crore in FY29E. It estimates EBITDA of Rs 2,798 crore, Rs 3,075 crore and Rs 3,686 crore, respectively.
| Financial year | Revenue | EBITDA | EBITDA margin |
|---|---|---|---|
| FY27E | Rs 8,779 crore | Rs 2,798 crore | 31.9% |
| FY28E | Rs 10,077 crore | Rs 3,075 crore | 30.5% |
| FY29E | Rs 11,607 crore | Rs 3,686 crore | 31.8% |
The broker bases its target valuation on 38 times FY29E EBITDA of Rs 3,686 crore. It considers the premium valuation justified by Laurus Labs' sustained capex programme and its ability to deliver strong numbers consistently.
Disclaimer: This is a summary of a research report published by the broker/research house identified above. The views, recommendations, target prices and estimates are those of the respective broker and do not represent DSIJ investment advice. The summary may be AI-assisted, hence please refer to the original report for complete details, disclosures and risks.
Copyright 2026 by DSIJ Wealth Advisory Pvt. Ltd. (Formerly Known as DSIJ Pvt. Ltd.)